The estimated Net Worth of Andre Turenne is at least $4.07 Миллион dollars as of 11 February 2021. Mr. Turenne owns over 7,977 units of Voyager Therapeutics Inc stock worth over $931,795 and over the last 6 years he sold VYGR stock worth over $293,264. In addition, he makes $2,844,090 as President, Chief Executive Officer и Director at Voyager Therapeutics Inc.
Sign up
Mr. Turenne VYGR stock SEC Form 4 insiders trading
G has made over 3 trades of the Voyager Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 7,977 units of VYGR stock worth $60,226 on 11 February 2021.
The largest trade he's ever made was selling 10,705 units of Voyager Therapeutics Inc stock on 21 January 2020 worth over $143,019. On average, G trades about 3,641 units every 48 days since 2018. As of 11 February 2021 he still owns at least 148,375 units of Voyager Therapeutics Inc stock.
You can see the complete history of Mr. Turenne stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
G. Andre Turenne biography
G. Andre Turenne serves as President, Chief Executive Officer, Director of the Company since July 2018. Prior to joining Voyager, Mr. Turenne held various positions at Sanofi, a biopharmaceutical company, including serving as Senior Vice President, Global Head of Business Development and Licensing, from November 2015 to March 2018, where he was responsible for partnering activities across all of Sanofi’s business units. Prior to that role, Mr. Turenne served as General Manager of Sanofi Genzyme Australia and New Zealand from January 2015 to November 2015 and previously served as Global Head of Strategy and Business Development for Genzyme from September 2012 to January 2015. Prior to its acquisition by Sanofi, Mr. Turenne served in several business development and commercial operations roles at Genzyme Corporation, a biopharmaceutical company, from 2006 to 2011. He began his career in the industry as a consultant at Kendall Strategies, the consulting arm of Feinstein Kean Healthcare, now part of Ogilvy. Mr. Turenne received a B.A. from Kalamazoo College and an M.B.A. from the Amos Tuck School of Business at Dartmouth College.
What is the salary of G Turenne?
As the President, Chief Executive Officer и Director of Voyager Therapeutics Inc, the total compensation of G Turenne at Voyager Therapeutics Inc is $2,844,090. There are 2 executives at Voyager Therapeutics Inc getting paid more, with Omar Khwaja having the highest compensation of $3,815,770.
How old is G Turenne?
G Turenne is 46, he's been the President, Chief Executive Officer и Director of Voyager Therapeutics Inc since 2018. There are 14 older and 1 younger executives at Voyager Therapeutics Inc. The oldest executive at Voyager Therapeutics Inc is Dr. Steven M. Paul M.D., 70, who is the Exec. Science Advisor & Director.
What's G Turenne's mailing address?
Andre's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC.,, 75 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Insiders trading at Voyager Therapeutics Inc
Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over $22,599,571 worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth $93,782,260 . The most active insiders traders include Sanofi, Capital, Llc Eco R1 и Biosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $966,976. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth $13,407.
What does Voyager Therapeutics Inc do?
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
What does Voyager Therapeutics Inc's logo look like?
Complete history of Mr. Turenne stock trades at Voyager Therapeutics Inc
Voyager Therapeutics Inc executives and stock owners
Voyager Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Omar Khwaja,
Chief Medical Officer and Head of Research and Development -
Robert Hesslein,
Senior Vice President, General Counsel -
G. Andre Turenne,
President, Chief Executive Officer, Director -
G. Andre Turenne,
Advisor -
Dr. Omar Khwaja M.D., Ph.D.,
Chief Medical Officer and Head of R&D -
Robert W. Hesslein,
Sr. VP & Gen. Counsel -
james Geraghty,
Independent Director -
Steven Hyman,
Independent Director -
Michael J. Higgins M.B.A.,
Interim CEO, Pres & Chairman -
Dr. Glenn F. Pierce M.D., Ph.D.,
Independent Director, Interim Chief Scientific Officer & Chief Medical Officer -
Dr. Steven M. Paul M.D.,
Exec. Science Advisor & Director -
Nancy Vitale,
Director -
Michelle Smith,
Chief Human Resource Officer -
Kelly Bales,
Senior Vice President, Head of Neuroscience -
Allison Dorval,
Chief Financial Officer -
Robin Swartz,
Chief Operating Officer -
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.,
Pres, CEO & Director -
Julie Burek,
VP of Fin. -
Dr. Mark A. Kay M.D., Ph.D.,
Founder -
Dr. Phillip D. Zamore,
Founder -
Dr. Mark A. Kay,
Founder -
Dr. Guangping Gao,
Founder -
Dr. Krystof Bankiewicz M.D., Ph.D.,
Founder -
Toby Ferguson,
Chief Medical Officer -
Sandell Jacquelyn Fahey,
Chief Legal Officer -
Rock Ventures Iii, L.P.Thir...,
-
Jane Henderson,
Sr. V.P. & CFO, Corp. Dev. -
Wendy L Dixon,
Director -
Jeff Goater,
Chief Financial Officer -
Sanofi,
-
Perry A Karsen,
Director -
Harbor Master Investors (Ca...,
10% owner -
Bernard Ravina,
Chief Medical Officer -
Matthew P. Ottmer,
Chief Operating Officer -
Dinah Ph.D. Sah,
Chief Scientific Officer -
Steven M Paul,
Director -
Andre Turenne,
President & CEO -
Robin Swartz,
Chief Operating Officer -
Biosciences Inc Neurocrine,
10% owner -
Michael J Higgins,
Director -
Mark J Levin,
Director -
Glenn Pierce,
Director -
Julie Burek,
VP, Finance -
Todd Alfred Carter,
Chief Scientific Officer -
Peter P. Pfreundschuh,
Chief Financial Officer -
Rock Ventures Iii, L.P.Thir...,
-
Catherine J Mackey,
Director -
Jude Onyia,
Director -
Grace Colon,
Director -
Capital, Llc Eco R1,
10% owner -
George A Scangos,
Director -
Nathan D. Jorgensen,
Chief Financial Officer